- Home
- UPLD vs STTK Comparison
UPLD vs STTK Comparison
Compare UPLD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPLD
- STTK
- Stock Information
- Founded
- UPLD 2010
- STTK 2016
- Country
- UPLD United States
- STTK United States
- Employees
- UPLD N/A
- STTK N/A
- Industry
- UPLD Computer Software: Prepackaged Software
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- UPLD Technology
- STTK Health Care
- Exchange
- UPLD Nasdaq
- STTK Nasdaq
- Market Cap
- UPLD 51.0M
- STTK 49.3M
- IPO Year
- UPLD 2014
- STTK 2020
- Fundamental
- Price
- UPLD $2.81
- STTK $1.00
- Analyst Decision
- UPLD Strong Buy
- STTK Hold
- Analyst Count
- UPLD 1
- STTK 5
- Target Price
- UPLD $4.50
- STTK $2.00
- AVG Volume (30 Days)
- UPLD 897.5K
- STTK 5.4M
- Earning Date
- UPLD 07-31-2025
- STTK 08-14-2025
- Dividend Yield
- UPLD N/A
- STTK N/A
- EPS Growth
- UPLD N/A
- STTK N/A
- EPS
- UPLD N/A
- STTK N/A
- Revenue
- UPLD $251,757,000.00
- STTK $2,997,000.00
- Revenue This Year
- UPLD N/A
- STTK N/A
- Revenue Next Year
- UPLD N/A
- STTK N/A
- P/E Ratio
- UPLD N/A
- STTK N/A
- Revenue Growth
- UPLD N/A
- STTK N/A
- 52 Week Low
- UPLD $1.69
- STTK $0.69
- 52 Week High
- UPLD $5.64
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- UPLD 64.99
- STTK 57.69
- Support Level
- UPLD $2.63
- STTK $0.79
- Resistance Level
- UPLD $3.17
- STTK $1.05
- Average True Range (ATR)
- UPLD 0.37
- STTK 0.10
- MACD
- UPLD 0.09
- STTK 0.02
- Stochastic Oscillator
- UPLD 49.31
- STTK 80.45
About UPLD Upland Software Inc.
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.